|
|
|
|
|
|
|
31.05.25 - 14:03
|
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma (GlobeNewswire EN)
|
|
|
Stafford, Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma. The longer follow-up of patients demonstrates a consistent and favorable tolerability profile as well as durable responses with a confirmed ORR of 56%. In addition, the Company provided details from a Trial in Progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor....
|
|
|
|
|
23.04.25 - 16:03
|
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois....
|
|
|
|
|
27.03.25 - 12:03
|
Immatics Announces Full Year 2024 Financial Results and Business Update (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024....
|
|
|
|
|
|
|
|
|
20.11.24 - 12:46
|
Immatics Aktie: Unglückliches Timing der Kapitalerhöhung (Aktiencheck)
|
|
|
Kulmbach (www.aktiencheck.de) - Immatics-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von Immatics N.V. (ISIN: NL0015285941, WKN: A2P72S, Ticker-Symbol: 4A3, NASDAQ-Symbol: IMTX) unter die Lupe.
Trotz vielversprechender Studiendaten befinde sich der Biotech-Hot-Stock Immatics seit einigen Wochen auf dem absteigenden Ast. [mehr]...
|
|
|
20.11.24 - 11:49
|
Immatics: Deutsche Biotech-Hoffnung unter Druck (Der Aktionaer)
|
|
|
Trotz vielversprechender Studiendaten befindet sich der Biotech-Hot-Stock Immatics sei einigen Wochen auf dem absteigenden Ast. Vor allem das Timing einer Kapitalmaßnahme ist einigen Marktteilnehmern offenbar sauer aufgestoßen. Die Personalie Robert F....
|
|
|
18.11.24 - 20:18
|
What Makes Immatics (IMTX) a New Buy Stock (Zacks)
|
|
|
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.10.24 - 02:54
|
Immatics Announces Pricing of $150 Million Public Offering (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $150 million. The offering is expected to close on October 15, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
